SCHEMBL160338

SCHEMBL160338

Cc1ccccc1[Se]c1ccccc1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.53
ACHE P22303 3/20 0.53
ALDH1A1 P00352 4/20 0.48
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA7 P43166 3/20 0.41
CA9 Q16790 2/20 0.41
CYP3A4 P08684 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP1A2 P05177 2/20 0.38
CYP2A6 P11509 2/20 0.38
LMNA P02545 1/20 0.35
ALOX12 P18054 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
ESR1 P03372 1/20 0.35
TAAR1 Q96RJ0 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887622 0.84 ACHE (0.43) TSHRACHEALDH1A1MAOAMAOB
SCHEMBL28270216 0.81 TSHR (0.53) TSHRACHEALDH1A1MAOAMAOB
SCHEMBL30206994 0.81 TSHR (0.53) TSHRACHEALDH1A1MAOAMAOB
SCHEMBL28396164 0.77
O-Xylene SCHEMBL2854068 0.71
O-Xylene SCHEMBL8216257 0.71 TSHR (1.00) TSHRACHEALDH1A1CA1CA2
O-Xylene SCHEMBL11035539 0.71 TSHR (1.00) TSHRACHEALDH1A1CA1CA2
O-Xylene SCHEMBL170581 0.71 TSHR (1.00) TSHRACHEALDH1A1CA1CA2
O-Xylene SCHEMBL10522915 0.71 TSHR (1.00) TSHRACHEALDH1A1CA1CA2
O-Xylene SCHEMBL11034038 0.71 TSHR (1.00) TSHRACHEALDH1A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10337030-B2 Microbially-mediated method for synthesis of metal chalcogenide nanoparticles UT-BATTELLE, LLC (US) 2019-07-02 US disclosed
US-9909221-B2 Controllable reductive method for synthesizing metal-containing particles UT-BATTELLE, LLC (US) 2018-03-06 US disclosed
US-20180010153-A1 MICROBIALLY-MEDIATED METHOD FOR SYNTHESIS OF METAL CHALCOGENIDE NANOPARTICLES U.S. DEPARTMENT OF ENERGY 2018-01-11 US disclosed
US-9768333-B2 Microbially-mediated method for synthesis of non-oxide semiconductor nanoparticles UT-BATTELLE, LLC (US) 2017-09-19 US disclosed
US-9637828-B2 Electrochemical method for synthesizing metal-containing particles and other objects UT-BATTELLE, LLC (US) 2017-05-02 US disclosed
US-9196760-B2 Methods for producing complex films, and films produced thereby UT-BATTELLE, LLC (US) 2015-11-24 US disclosed
WO-2014164954-A1 ELECTROCHEMICAL METHOD FOR SYNTHESIZING METAL-CONTAINING PARTICLES AND OTHER OBJECTS UT-BATTELLE, LLC (US) 2014-10-09 WO disclosed
WO-2014164950-A1 METHOD FOR SYNTHESIZING METAL OXIDE PARTICLES UT-BATTELLE, LLC (US) 2014-10-09 WO disclosed
WO-2014164953-A1 CONTROLLABLE REDUCTIVE METHOD FOR SYNTHESIZING METAL-CONTAINING PARTICLES UT-BATTELLE, LLC (US) 2014-10-09 WO disclosed
US-20140273147-A1 METHOD FOR SYNTHESIZING METAL OXIDE PARTICLES OAK RIDGE ASSOCIATED UNIVERSITIES 2014-09-18 US disclosed
US-20040237384-A1 Fuel compositions exhibiting improved fuel stability OCTANE INTERNATIONAL, LTD. 2004-12-02 US disclosed
US-20040176336-A1 Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium RODRIGUEZ GUSTAVO C (US) 2004-09-09 US disclosed
US-20040106587-A1 Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium NEW LIFE PHARMACEUTICALS INC. 2004-06-03 US disclosed
US-6652608-B1 Fuel compositions exhibiting improved fuel stability OCTANE INTERNATIONAL, LTD. 2003-11-25 US disclosed
US-6511970-B1 Multiphasic hormonal regimen wherein at least one of the daily dosages has at least 0.5 mg of norgestrel and an estrogen component NEW LIFE PHARMACEUTICALS INC. 2003-01-28 US disclosed
US-20010044431-A1 Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium NEW LIFE PHARMACEUTICALS INC. 2001-11-22 US disclosed
EP-1051461-A2 FUEL COMPOSITIONS EMPLOYING CATALYST COMBUSTION STRUCTURE ORR, William C. (US) 2000-11-15 EP disclosed
WO-1999066009-A2 FUEL COMPOSITIONS EMPLOYING CATALYST COMBUSTION STRUCTURE ORR WILLIAM C (US) 1999-12-23 WO disclosed
EP-0954558-A1 FUEL COMPOSITIONS EXHIBITING IMPROVED FUEL STABILITY ORR, William C. (US) 1999-11-10 EP disclosed
WO-1998026028-A1 FUEL COMPOSITIONS EXHIBITING IMPROVED FUEL STABILITY ORR WILLIAM C (US) 1998-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106587-A1 Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium HDGF, PGF, OGFRL1 TSHR 1759/4885ACHE 2980/4885ALDH1A1 929/4885
US-20010044431-A1 Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium HDGF, PGF, OGFRL1 TSHR 1759/4885ACHE 2980/4885ALDH1A1 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.